AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29627888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) (1064 nm)
Number of subjects: 70
Study 29627888 — intervention group
Group type: COMPARATOR
Intervention: Low-Level Laser Therapy (LLLT) (904 nm)
Number of subjects: 70
Study 28510619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (9.3% of participants)
Number of subjects: 3069
Study 28510619 — intervention group
Group type: COMPARATOR
Intervention: No diabetes (90.7% of participants)
Number of subjects: 3069
Study 26230432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogymnastics training protocol, performed 5 times a week for 12 weeks, intensity 50-60% of maximum heart rate
Number of subjects: 26
Study 26230432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 23499637 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback defibrillator (Group 1)
Number of subjects: 298
Study 23499637 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-feedback defibrillator (Group 2)
Number of subjects: 298
Study 23499637 — intervention group
Group type: COMPARATOR
Intervention: Non-feedback defibrillator (Control group)
Number of subjects: 298
Study 22069361 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/F 400/24 μg/day
Number of subjects: 18
Study 22069361 — intervention group
Group type: COMPARATOR
Intervention: FP/S 500/100 μg/day
Number of subjects: 18
Study 22069361 — intervention group
Group type: COMPARATOR
Intervention: BDP/F vs FP/S
Number of subjects: 18
Study 19007693 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-multidetector row coronary computed tomographic angiography (CCTA)
Number of subjects: 230
Study 16621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg loading dose (LD) / 5 mg maintenance dose (MD)
Number of subjects: 101
Study 16621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 40 mg LD / 7.5 mg MD
Number of subjects: 101
Study 16621870 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg LD / 75 mg MD
Number of subjects: 101
Study 16621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg MD
Number of subjects: 101
Study 16621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 15 mg MD
Number of subjects: 101
Study 15286870 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic bupivacaine 0.75% with epinephrine 1:200.000
Number of subjects: 97
Study 15286870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% with epinephrine 1:200.000
Number of subjects: 97
Study 15286870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 97
Study 15286870 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 97
Study 11709686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 69
Study 11709686 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden during radiotherapy and pilocarpine for 6 weeks after
Number of subjects: 69
Study 11709686 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither drug)
Number of subjects: 69
Study 9212125 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcatheter spinal anesthesia (CSA)
Number of subjects: 60
Study 9212125 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural technique (CSE)
Number of subjects: 60
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-follicular phase
Number of subjects: 273
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-follicular phase
Number of subjects: 273
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 273
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-follicular phase with abundant cervical mucus
Number of subjects: 273
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial cavity movements
Number of subjects: 273
Study 7962368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial cavity echo‐free space content
Number of subjects: 273
Study 3069002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 20
Study 3069002 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (Control)
Number of subjects: 20
Study 31780201 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal A1C (<5.7%)
Number of subjects: 1159
Study 31780201 — intervention group
Group type: COMPARATOR
Intervention: Prediabetes (≥5.7 and <6.5%)
Number of subjects: 1159
Study 31780201 — intervention group
Group type: COMPARATOR
Intervention: Undiagnosed type 2 diabetes (≥6.5%)
Number of subjects: 1159
Study 28923465 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in addition to capillary glucose monitoring
Number of subjects: 325
Study 28923465 — intervention group
Group type: COMPARATOR
Intervention: Capillary glucose monitoring alone (Control)
Number of subjects: 325
Study 25666414 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee bean polyphenols (CBPs)
Number of subjects: 13
Study 25666414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no CBPs)
Number of subjects: 13
Study 23431369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 83
Study 20665472 — intervention group
Group type: EXPERIMENTAL
Intervention: E. laciniata extract ointment
Number of subjects: 40
Study 20665472 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 40
Study 19690439 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17468792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary postoperative rehabilitation programme
Number of subjects: 199
Study 17468792 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative routines
Number of subjects: 199
Study 14691426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer training
Number of subjects: 46
Study 14691426 — intervention group
Group type: COMPARATOR
Intervention: Electrical muscle stimulator training
Number of subjects: 46
Study 11228355 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine without aluminium hydroxide adjuvant
Number of subjects: 20
Study 11228355 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine with aluminium hydroxide adjuvant
Number of subjects: 20
Study 11228355 — intervention group
Group type: COMPARATOR
Intervention: 23-valent PS vaccine (control)
Number of subjects: 20
Study 11228355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conjugate vaccines
Number of subjects: 20
Study 9508168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MTZ) 8 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Number of subjects: 489
Study 9508168 — intervention group
Group type: COMPARATOR
Intervention: Daunomycin (DNR) 30 mg/m2 on days 1, 2, and 3 plus cytarabine (Ara‐C) 100 mg/m2 on days 1 to 7
Number of subjects: 489
Study 9508168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD-Ara-C) 10 mg/m2 subcutaneously every 12 hours for 12 days every 6 weeks
Number of subjects: 489
Study 9508168 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after initial chemotherapy
Number of subjects: 489
Study 9508168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MTZ)
Number of subjects: 489
Study 9508168 — intervention group
Group type: COMPARATOR
Intervention: Daunomycin (DNR)
Number of subjects: 489
Study 9508168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LD-Ara-C)
Number of subjects: 489
Study 8310991 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium seed (10 g/d for 3 weeks)
Number of subjects: 21
Study 8310991 — intervention group
Group type: COMPARATOR
Intervention: Psyllium husk (10 g/d for 3 weeks)
Number of subjects: 21
Study 3337484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarct extension
Number of subjects: 848
Study 3337484 — intervention group
Group type: COMPARATOR
Intervention: Patients without myocardial infarct extension
Number of subjects: 848
Study 3337484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent ischemic pain, previous myocardial infarction, and ST segment depression
Number of subjects: 848
Study 3337484 — intervention group
Group type: COMPARATOR
Intervention: Patients without any of the risk factors
Number of subjects: 848
Study 3337484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients surviving initial hospitalization
Number of subjects: 848
Study 31054254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based CCT (Fit Brains) 3×/week for 1 hour plus 3×/week home-based training
Number of subjects: 124
Study 31054254 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based CCT preceded by exercise (Ex-CCT) 3×/week for 1 hour plus 3×/week home-based training
Number of subjects: 124
Study 31054254 — intervention group
Group type: COMPARATOR
Intervention: Group-based balanced and toned (BAT) classes 3×/week for 1 hour
Number of subjects: 124
Study 29976469 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical cystectomy
Number of subjects: 350
Study 29976469 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 350
Study 27569003 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention (FCG)
Number of subjects: 12
Study 27569003 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAUG)
Number of subjects: 12
Study 27569003 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-related negativity (ERN)
Number of subjects: 12
Study 26677669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziyin Huoxue Granule (ZHG) combined with glucocorticoids and antibiotics
Number of subjects: 70
Study 26677669 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids and antibiotics alone (Control)
Number of subjects: 70
Study 23580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with a transtendon technique (group 1)
Number of subjects: 60
Study 23580030 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic full-thickness conversion and repair of the lesion (group 2)
Number of subjects: 60
Study 23580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19945276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotip
Number of subjects: 44
Study 19945276 — intervention group
Group type: COMPARATOR
Intervention: Neuropen
Number of subjects: 44
Study 17881218 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic intervention during the second stage of labor
Number of subjects: 81
Study 17881218 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean delivery
Number of subjects: 81
Study 17881218 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anesthesiologist
Number of subjects: 81
Study 17881218 — intervention group
Group type: EXPERIMENTAL
Intervention: Time anesthesiologist present during delivery
Number of subjects: 81
Study 17164738 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous preoperative reviparin (4,200 anti Xa IU) once daily
Number of subjects: 2018
Study 17164738 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (7,500 IU) twice daily
Number of subjects: 2018
Study 12836149 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (soft music without lyrics for 3 hours)
Number of subjects: 110
Study 12836149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 110
Study 10712343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) at 880 microg
Number of subjects: 20
Study 10712343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8857919 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies against oxidized LDL in NIDDM patients
Number of subjects: 91
Study 8857919 — intervention group
Group type: COMPARATOR
Intervention: Autoantibodies against oxidized LDL in control subjects
Number of subjects: 91
Study 8857919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimal-medial thickness of the common carotid artery in NIDDM patients
Number of subjects: 91
Study 8857919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimal-medial thickness of the carotid bifurcation in NIDDM patients
Number of subjects: 91
Study 8857919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular events in NIDDM patients
Number of subjects: 91
Study 1323926 — intervention group
Group type: COMPARATOR
Intervention: Soy phosphatidylcholine (PC) 27 g
Number of subjects: 20
Study 1323926 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy phosphatidylcholine (PC) 18 g
Number of subjects: 20
Study 1323926 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (SF)
Number of subjects: 20
Study 1323926 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SY)
Number of subjects: 20
Study 6507905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bupivacaine (2 mg/min for 3 hr)
Number of subjects: 8
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic neuropathy (DN) defined by neuropathic symptoms and a vibration perception threshold (VPT) ≥ 15 V.
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk for diabetic foot ulceration (DFU) defined by VPT ≥ 25 V.
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic foot ulceration (DFU).
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetic neuropathy (DN).
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycaemic control (HbA1c ≥ 9%).
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidaemia.
Number of subjects: 1082
Study 31913560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension.
Number of subjects: 1082
Study 29439083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led preventative psychological intervention
Number of subjects: 24
Study 29439083 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 26453222 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 131
Study 26453222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 131
Study 26453222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 131
Study 26453222 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin vs Tamsulosin
Number of subjects: 131
Study 24854808 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH intervention
Number of subjects: 84
Study 24854808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 21035214 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream GP IIb/IIIa inhibitors therapy
Number of subjects: 19469
Study 20939113 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO1 (30,000 U of Epo before PM and at the end of surgery)
Number of subjects: 27
Study 20939113 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO2 (60,000 U of Epo before PM)
Number of subjects: 27
Study 20939113 — intervention group
Group type: COMPARATOR
Intervention: STRD (100 mg of hydrocortisone before PM and on postoperative days 1, 2, 3)
Number of subjects: 27
Study 18522627 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-706 (50 mg oral dose)
Number of subjects: 0
Study 18522627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16108924 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT) intervention; prompted voiding combined with individualized, functionally oriented endurance and strength‐training exercises offered four times per day, 5 days per week, for 8 weeks
Number of subjects: 107
Study 16108924 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Incidental Training (FIT) intervention
Number of subjects: 107
Study 16108924 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2 before receiving FIT)
Number of subjects: 107
Study 16108924 — intervention group
Group type: COMPARATOR
Intervention: Functional Independence Measure (FIM) for locomotion and toileting
Number of subjects: 107
Study 12952110 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 289
Study 12952110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 10372241 — intervention group
Group type: EXPERIMENTAL
Intervention: KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan)
Number of subjects: 11
Study 10372241 — intervention group
Group type: COMPARATOR
Intervention: matched placebo wheat bran fiber biscuits
Number of subjects: 11
Study 8972416 — intervention group
Group type: COMPARATOR
Intervention: Double gloves
Number of subjects: 341
Study 8972416 — intervention group
Group type: EXPERIMENTAL
Intervention: Single orthopedic gloves
Number of subjects: 341
Study 1679917 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine prophylaxis
Number of subjects: 0
Study 1679917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 0
Study 6352606 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 137
Study 6352606 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime
Number of subjects: 137
Study 6352606 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin and metronidazole
Number of subjects: 137
Study 6352606 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime and metronidazole
Number of subjects: 137
Study 31928474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground Chia Seed
Number of subjects: 30
Study 31337877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 202
Study 31337877 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 202
Study 31337877 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET SUVmax ≥10
Number of subjects: 202
Study 29663901 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led surveillance and treatment in intervention villages (5 villages, 997 residents)
Number of subjects: 2189
Study 29663901 — intervention group
Group type: COMPARATOR
Intervention: Control villages (3 villages, 1,192 residents)
Number of subjects: 2189
Study 26266647 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm buildup
Number of subjects: 45
Study 26266647 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm buildup
Number of subjects: 45
Study 26266647 — intervention group
Group type: EXPERIMENTAL
Intervention: No buildup (endocrown)
Number of subjects: 45
Study 24154863 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel (60 mg loading dose / 10 mg daily maintenance dose)
Number of subjects: 42
Study 24154863 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose prasugrel (10 mg daily maintenance dose)
Number of subjects: 42
Study 24154863 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel (900 mg loading dose / 150 mg daily maintenance dose)
Number of subjects: 42
Study 23034424 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing and tongue cleaning with tooth-and-tongue gel
Number of subjects: 54
Study 23034424 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing with reference toothpaste and tongue cleaning
Number of subjects: 54
Study 23034424 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing with reference toothpaste
Number of subjects: 54
Study 20854964 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy (losartan or atenolol)
Number of subjects: 778
Study 20854964 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal in-treatment transmitral flow pattern
Number of subjects: 778
Study 17222276 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape exposure during delirium tremens
Number of subjects: 60
Study 17222276 — intervention group
Group type: COMPARATOR
Intervention: Control group without videotape experience
Number of subjects: 60
Study 15270253 — intervention group
Group type: EXPERIMENTAL
Intervention: qingluo tongbi granules (QTG)
Number of subjects: 63
Study 15270253 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium glycosides (Control)
Number of subjects: 63
Study 12495902 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Progenitor Cell (PBPC)
Number of subjects: 26
Study 12495902 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow (BM)
Number of subjects: 26
Study 12495902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' spontaneous responses
Number of subjects: 26
Study 11185631 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 120 mg
Number of subjects: 12
Study 11185631 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study 8825366 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (chenodeoxycholate)
Number of subjects: 0
Study 8825366 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (ursodeoxycholate)
Number of subjects: 0
Study 8825366 — intervention group
Group type: COMPARATOR
Intervention: Octreotide alone
Number of subjects: 0
Study 8825366 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of CDCA with octreotide
Number of subjects: 0
Study 8825366 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of UDCA with octreotide
Number of subjects: 0
Study 1479687 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 49
Study 3988385 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectancy/suggestions for amnesia
Number of subjects: 120
Study 3988385 — intervention group
Group type: EXPERIMENTAL
Intervention: No expectancy/suggestions for amnesia
Number of subjects: 120
Study 3988385 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectancy/no suggestions
Number of subjects: 120
Study 3988385 — intervention group
Group type: EXPERIMENTAL
Intervention: No expectancy/no suggestions
Number of subjects: 120
Study 3988385 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonhypnotized)
Number of subjects: 120
Study 30540701 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management interventions
Number of subjects: 495